Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study

BACKGROUND: Major depressive disorder (MDD) is a global health concern. This study examined the efficacy, safety and tolerability of an extended-release (ER) formulation of levomilnacipran, an antidepressant approved for the treatment of MDD in adults. METHODS: This 10-week (1-week placebo run-in pe...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Bakish, David, Bose, Anjana, Gommoll, Carl, Chen, Changzheng, Nunez, Rene, Greenberg, William M., Liebowitz, Michael, Khan, Arif
Formato: Artigo
Idioma:Inglês
Publicado: Canadian Medical Association 2014
Assuntos:
Research Papers
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3868664/
https://ncbi.nlm.nih.gov/pubmed/24144196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1503/jpn.130040
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares